Q-omics provides the consensus-scored KIAA1549 profile across patient tissues and cancer cell-line models. KIAA1549 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KIAA1549 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, KIAA1549 RNA expression shows 21,098 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where KIAA1549 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIAA1549 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIAA1549 survival associations across molecular data types. KIAA1549 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIAA1549 RNA expression–survival associations across cancer types. High KIAA1549 expression shows unfavorable associations in MESO, CESC and PAAD, but favorable associations in KIRC, OV and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KIAA1549 RNA expression.
This table summarizes KIAA1549 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KIAA1549. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIAA1549 shows higher tumor expression in COAD, LIHC, BLCA, HNSC, STAD and UCEC. The COAD box plot shows higher KIAA1549 RNA expression in tumor versus normal tissue (log2 FC = +2.258, t-test p < 0.001).
This table shows molecular features associated with KIAA1549 in patient tissues and cancer cell lines. In patient samples, KIAA1549 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIAA1549 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
